Visit

Valuation

Smartphone royalty stack continues multi-year decline, says analyst

Financial disclosures from four major publicly-listed patent owners suggest that their collective licensing revenues are on a downward trend

1 Sep 2021

Qualcomm licensing chief is number one in IAM's Market Makers ranking of the world's IP business leaders

The Long Read: Alex Rogers heads the list of individuals who have shaped the global patent licensing and deals markets over the past year, with senior executives from both corporates and NPEs making up the rest of the top 10

31 Aug 2021

Alibaba deploys tool to provide price guidance for patents going under the hammer

Intangio, developed by valuation specialists Inngot and IP services firm Rouse, is helping insolvency practitioners set a data-driven reserve price for patent assets at bankruptcy auctions

Latest

View all

30 Aug 2021

IP could become a $100 billion premium market, says Aon CEO

Greg Case has been bullish about the sector for a while and if he is right it could finally mean the birth of the asset class so many have been waiting for Read more

26 Aug 2021

Pfizer’s $2.3 billion spend on CD47 inhibitors shows how oncology IP continues to drive pharma deal-making

The acquisition of the cutting-edge haematology candidates is just the latest development in the booming immuno-oncology market Read more

23 Aug 2021

Toyota’s self-driving haul from Lyft includes 100+ US patent assets

Patents change hands after Japanese carmaker buys Lyft’s self-driving tech for $550 million Read more

18 Aug 2021

Japan’s corporate watchdog calls for high-level emphasis on intellectual property

Changes to the country’s corporate governance code encourage boards to pay more attention to IP strategy Read more

News

View all

22 Dec 2020

The keys to effective IP monetisation

Patent licensing is as much an art as it is a science, explain some of those featured in the new IAM Strategy 300 Global Leaders guide Read more

19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

9 Nov 2020

Pfizer’s covid vaccine found 90% effective, but raises IP questions

Company CEO proclaims “a great day for science and humanity”, but there are patent, know-how and data uncertainties to overcome Read more

20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

Analysis

View all

12 Aug 2021

mRNA IP will be hot property beyond the pandemic

$3.2 billion Sanofi deal is unlikely to be the last as Big Pharma seeks to consolidate its position in the cutting-edge field Read more

5 Aug 2021

Healthcare Royalty Partners’ $750 million IPO to be next milestone for a booming market

The company is hoping to raise cash to help expand its purchasing power when acquiring pharmaceuticals revenue streams Read more

4 Aug 2021

Investor interest in IP is about more than big money verdicts, claims Ocean Tomo transactions chief

Ten-figure awards in the patent space have caught capital’s attention, says Ocean Tomo's Ryan Zurek, but so has the IP market’s resilience in the face of economic turbulence Read more

20 Jul 2021

Biopharma M&A has fallen off a cliff – but IP owners in the sector have reasons to be cheerful

The number and value of acquisitions have both tumbled further than in the early months of 2020 Read more

Insights

View all

8 Jun 2020

From French fancy to global community – celebrating 100 issues of IAM

Founder and editor in chief Joff Wild looks back on 17 years of IAM Read more

1 Oct 2017

A round-up of IP-related quotes, observations and opinions from the recent past …

30 Sep 2016

McRO gives hope to US patent owners, but Section 101 uncertainty remains

After two years of uncertainty and no little gloom, a recent Federal Circuit decision may just herald the long-awaited swing-back in the pendulum that software patent owners in the United States have been waiting for. Some, though, still believe that Congress must bite the bullet and take a look at Section 101 Read more

1 Aug 2016

Brexit leaves the UPC in limbo – and that’s no bad thing

The UK vote to leave the European Union may have surprised and disappointed many in the IP community, but a rush to bypass the decision and implement the unitary patent package would be a mistake

Twitter

22 Sep 2021

@IAM_Alerts Leahy aims to reverse USPTO’s discretionary denials in new PTAB reform bill https://t.co/tfj6h9AScK https://t.co/cl8Y0cCEZ3 Read more

22 Sep 2021

@IAM_Alerts More details of the proposed legislation's content have been shared by the Leahy team. We will have them on the IAM… https://t.co/D4VjaljD5M Read more

22 Sep 2021

@IAM_Alerts This week's IAM Long Read - Sector-by-sector analysis reveals that transport, financial services and networking all… https://t.co/7UKx6CvbmW Read more

22 Sep 2021

@IAM_Alerts Philips links with TCL in its latest China-focused patent deal https://t.co/um5GATnkXR https://t.co/RnOPNuw8LR Read more

Valuation

Qualcomm licensing chief is number one in IAM's Market Makers ranking of the world's IP business leaders

Alibaba deploys tool to provide price guidance for patents going under the hammer

Latest

IP could become a $100 billion premium market, says Aon CEO

Pfizer’s $2.3 billion spend on CD47 inhibitors shows how oncology IP continues to drive pharma deal-making

Toyota’s self-driving haul from Lyft includes 100+ US patent assets

Japan’s corporate watchdog calls for high-level emphasis on intellectual property

News

The keys to effective IP monetisation

Your guide to covid-19 vaccine stakeholders’ IP strategies

Pfizer’s covid vaccine found 90% effective, but raises IP questions

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

Analysis

mRNA IP will be hot property beyond the pandemic

Healthcare Royalty Partners’ $750 million IPO to be next milestone for a booming market

Investor interest in IP is about more than big money verdicts, claims Ocean Tomo transactions chief

Biopharma M&A has fallen off a cliff – but IP owners in the sector have reasons to be cheerful

Insights

From French fancy to global community – celebrating 100 issues of IAM

A round-up of IP-related quotes, observations and opinions from the recent past …

McRO gives hope to US patent owners, but Section 101 uncertainty remains

Brexit leaves the UPC in limbo – and that’s no bad thing

Trending

Smartphone royalty stack continues multi-year decline, says analyst

How to value a professional services firm in an M&A transaction

Pfizer’s covid vaccine found 90% effective, but raises IP questions

Your guide to covid-19 vaccine stakeholders’ IP strategies

Qualcomm licensing chief is number one in IAM's Market Makers ranking of the world's IP business leaders

Twitter